Navigation Links
Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
Date:10/25/2010

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences -- CARMIEL, Israel, Oct. 25 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News Click to view news release full screen  

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences

 

CARMIEL, Israel, Oct. 25 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the Oppenheimer 21st Annual Healthcare Conference in New York and the World Orphan Drug Congress 2010 in Geneva. The conference schedule is as follows:Oppenheimer 21st Annual Healthcare ConferenceCorporate Presentation, November 2 at 12:00 PM ETWaldorf Astoria Hotel, New York, NYA webcast of this presentation will be available at www.protalix.com on the event calendar pageWorld Orphan Drug Congress 2010Presentation, November 30 at 9:10 AM CESTCrown Plaza Hotel, Geneva, SwitzerlandAbout ProtalixProtalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based expression system.  Protalix's ProCellEx™ presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses.  Protalix is also advancing additional recombinant biopharmaceutical drug development programs.  Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease. The Company's new drug application (NDA) for taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.

Investor Contact: Marcy NanusThe Trout Group, LLCTelephone: 646-378-2927Email: mnanus@troutgroup.com
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
2. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
3. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
4. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
5. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
6. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
7. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
8. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
9. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... and PORTLAND, Ore. , Feb. ... optimization company, is pleased to announce the acquisition of ... community and rural access hospitals. Along with providing traditional ... 340B consulting services to assist clients in navigating the ... Love , CEO of Wellpartner. --> James ...
(Date:2/11/2016)... DUBLIN, February 11, 2016 Transformational M&A ... with Baxalta   --> Transformational M&A achieved through ...   --> Transformational M&A achieved through NPS ... Positioned for future growth with most robust pipeline ... Positioned for future growth with most robust pipeline in ...
(Date:2/11/2016)... , February 11, 2016 ... release of a new research report, titled "Sports Medicine Devices ... Forecast, 2013 - 2019". According to the report, the global ... 4.40% CAGR from 2013 to 2019, growing from a value ... --> --> The global ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 11, 2016 , ... Atlantic Information Services, Inc. (AIS) is ... Case Study for Plans and Purchasers.” Executives from Intel Corp. and Providence Health ... value-based health benefits program Connected Care, will discuss the challenges they faced (and ...
(Date:2/11/2016)... Australia (PRWEB) , ... February 11, 2016 , ... ... potential ?" motivational speaker, trainer and author Ray Clarke poses a question as ... personal fulfillment . In his book, "Being in the Being" (published by Partridge ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield ... charity program created to assist the people of their local community. The agency ... organizations and community leaders. Their hope is to bring awareness to important local ...
(Date:2/11/2016)... ... 2016 , ... Talix today announced that Clive Fields, MD, ... at the 2016 HIMSS Annual Conference & Exhibition, taking place February 29 – ... Coding for Care: Using Data Analytics for Risk Adjustment ,” Dr. Fields will ...
(Date:2/11/2016)... , ... February 11, 2016 , ... The annual list ... on evaluation of DataPoint’s team dedication and commitment to the SharePoint ecosystem. ... the annual list. The panel’s goal is to recognize and promote technology entrepreneurship. ...
Breaking Medicine News(10 mins):